(Q38019954)

27 August 2017

Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). (English)

1 reference

27 August 2017

1 reference

A Oliver Sartor

1

1 reference

PubMed ID

22712568

27 August 2017

John M Fitzpatrick

series ordinal

2

1 reference

27 August 2017

19 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

110

1 reference

27 August 2017

328-335

1 reference

27 August 2017

3

1 reference

27 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Physician visits prior to treatment for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Pain management in the patient with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Intermittent chemotherapy for metastatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Update on tubulin-binding agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

The medical management of prostate cancer: a multidisciplinary team approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Castration-resistant prostate cancer: current and emerging treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10818.X

10.1111/J.1464-410X.2011.10818.X

21 January 2018

Identifiers

DOI

1 reference

release_2z3ong42z5chfhu6l2kr7xncme

27 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2z3ong42z5chfhu6l2kr7xncme

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22712568

1 reference

PubMed ID

22712568